medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2025, Number 3

<< Back Next >>

Rev Mex Urol 2025; 85 (3)

Frequency and severity of lower urinary tract symptomatology related to prostate disease in a mexican population

Pérez-Chan M, Hernández-Hernández MI, de la Cruz-Solís SP, Quiroz-Gómez S, Celorio-Méndez KS, Guzmán-Priego CG

Language: English
References: 30
Page: 1-11
PDF size: 165.02 Kb.


ABSTRACT

Objective: To evaluate the frequency and severity of prostate symptoms in men aged 40-70 years in Tabasco, Mexico, where the lack of local data limits prevention strategies and early detection of pathologies such as prostate cancer and benign prostatic hyperplasia (BPH).
Methods: Descriptive, cross-sectional study (February-August 2024) of 383 randomly selected men. The International Prostate Symptom Scale (IPSS) and a socio-demographic questionnaire were used. Data were analyzed with SPSS v25 using descriptive statistics and Spearman correlation.
Results: 79.1 % of participants reported at least one lower urinary tract symptom (LUTS) in the last month, with nocturia (26.4 %) and urinary frequency (46 %) being the most common. Symptoms were mild in 54 %, moderate in 31.2 % and severe in 7 %. Age showed a positive correlation with symptom severity (0.186, p‹0.001), whereas medical history (hypertension: 20.9 %, diabetes: 16.7 %) showed a negative correlation (-0.265, p‹0.001). 44.9 % had no relevant medical history.
Conclusions: The high prevalence of LUTS in Tabasco highlights the need for educational campaigns and free screening to reduce underdiagnosis and associated mortality. The association with age and comorbidities reinforces the importance of addressing these factors in public health strategies.


REFERENCES

  1. Chiang HM, Susaeta R, Finsterbusch C.Síntomas urinarios bajos, prostatismo,hiperplasia prostática, uropatía obstructiva baja,¿todo una misma cosa? Revista Médica ClínicaLas Condes. 2014;25(1): 149–157. https://doi.org/10.1016/S0716-8640(14)70021-5.

  2. Bergengren O, Pekala KR, Matsoukas K,Fainberg J, Mungovan SF, Bratt O, et al. 2022Update on Prostate Cancer Epidemiology andRisk Factors-A Systematic Review. EuropeanUrology. 2023;84(2): 191–206. https://doi.org/10.1016/j.eururo.2023.04.021.

  3. Luque Zurita D, Pérez Valverde Á, UniversidadNacional de San Agustín, Arequipa – Perú,Lizárraga Vargas L, Ministerio Público,Arequipa – Perú, Campos Beltrán S, et al.EPIDEMIOLOGIA DE LA HIPERPLASIAPROSTATICA BENIGNA (BPH). Revista dePostgrado SCIENTIARVM. 2015;7(1): 27–34.https://doi.org/10.26696/sci.epg.0127.

  4. Ng M, Leslie SW, Baradhi KM. BenignProstatic Hyperplasia. In: StatPearls. StatPearlsPublishing; 2025. http://www.ncbi.nlm.nih.gov/books/NBK558920/

  5. Wang YB, Yang L, Deng YQ, Yan SY, Luo LS,Chen P, et al. Causal relationship betweenobesity, lifestyle factors and risk of benignprostatic hyperplasia: a univariable andmultivariable Mendelian randomization study.Journal of Translational Medicine. 2022;20(1):495. https://doi.org/10.1186/s12967-022-03722-y.

  6. Robles-Rodríguez A, Garibay-Huarte TR,Acosta Arreguín E, Morales López S. Lapróstata: generalidades y patologías másfrecuentes. Revista de la Facultad de Medicina.2019;62(4):41–54.

  7. Franco JV, Jung JH, Imamura M, BorofskyM, Omar MI, Escobar Liquitay CM, et al.Minimally invasive treatments for lowerurinary tract symptoms in men with benignprostatic hyperplasia: a network metaanalysis.The Cochrane Database of SystematicReviews. 2021;7(7): CD013656. https://doi.org/10.1002/14651858.CD013656.pub2.

  8. Merriel SWD, Pocock L, Gilbert E, CreavinS, Walter FM, Spencer A, et al. Systematicreview and meta-analysis of the diagnosticaccuracy of prostate-specific antigen (PSA) forthe detection of prostate cancer in symptomaticpatients. BMC Medicine. 2022;20(1): 54. https://doi.org/10.1186/s12916-021-02230-y.

  9. Awedew AF, Han H, Abbasi B, Abbasi-Kangevari M, Ahmed MB, Almidani O, et al.The global, regional, and national burden ofbenign prostatic hyperplasia in 204 countriesand territories from 2000 to 2019: a systematicanalysis for the Global Burden of Disease Study2019. The Lancet Healthy Longevity. 2022;3(11):e754–e776. https://doi.org/10.1016/S2666-7568(22)00213-6.

  10. Marzo Castillejo M, Peña López F, AlonsoCoello P, Mascort Roca JJ. Actualización enprevención y tratamiento del cáncer de próstata.Atencion Primaria. 2002;30(1): 57–63. https://doi.org/10.1016/S0212-6567(02)78963-4.

  11. Guzman-Esquivel J, Solórzano HPG, EncisoID. Epidemiología del cáncer de próstata:análisis comparativo de los principales cánceresurológicos. Revista Mexicana de Urología.2025;85(1): 1–10. https://doi.org/10.48193/cpthsn35.

  12. Zhang AY, Xu X. Prevalence, Burden, andTreatment of Lower Urinary Tract Symptomsin Men Aged 50 and Older: A SystematicReview of the Literature. SAGE open nursing.2018;4: 2377960818811773. https://doi.org/10.1177/2377960818811773.

  13. Welliver C, Feinstein L, Ward JB, KirkaliZ, Martinez-Miller E, Matlaga BR, et al.Evolution of healthcare costs for lower urinarytract symptoms associated with benignprostatic hyperplasia. International Urology andNephrology. 2022;54(11): 2797–2803. https://doi.org/10.1007/s11255-022-03296-0.

  14. Oraá-Tabernero N, Cruzado JA. Ansiedad ydepresión en hombres con cáncer de próstataen función del tipo de tratamiento y su relacióncon la calidad de vida y la información recibida.Psicooncología. 2019;16(2): 329–344. https://doi.org/10.5209/psic.65594.

  15. Sánchez KS, Sánchez MC, Acuña VR, ChanMP. Prevalencia de factores de riesgo ysintomatología prostática en indígenas deTabasco. Revista Cuidarte. 2021;12(2). https://doi.org/10.15649/cuidarte.1264.

  16. Reyes-Vallejo AGML. Evolución en eltratamiento médico de los síntomas deltracto urinario bajo en hombres. RevistaMexicana de Urología. 2015;75(1). https://doi.org/10.48193/revistamexicanadeurologa.v75i1.236.

  17. Torres-Sánchez LE, Espinoza-Giacinto R, Rojas-Martínez R, Escamilla-Nuñez C, Vázquez-Salas RA, Campuzano JC, et al. Prostate cancermortality according to marginalization status inMexican states from 1980 to 2013. Salud Públicade México. 2016;58(2): 179–186.

  18. Martin RM, Turner EL, Young GJ, MetcalfeC, Walsh EI, Lane JA, et al. Prostate-SpecificAntigen Screening and 15-Year ProstateCancer Mortality: A Secondary Analysis ofthe CAP Randomized Clinical Trial. JAMA.2024;331(17): 1460–1470. https://doi.org/10.1001/jama.2024.4011.

  19. Ángeles-Garay U, Sandoval-Sánchez JJ,Sánchez-Martínez LC, Acosta-Cazares B,Ruíz-Betancourt BS, Ángeles-Garay U, et al.Conducta sexual y otros factores de riesgo paracáncer de próstata. Revista mexicana de urología.

  20. 2019;79(5).20. Larkin D, Birtle AJ, Bradley L, Dey P, MartinCR, Pilkington M, et al. A systematic review ofdisease related stigmatization in patients livingwith prostate cancer. PLOS ONE. 2022;17(2):e0261557. https://doi.org/10.1371/journal.pone.0261557.

  21. Williams D, Ryce A. Minimally-InvasiveTreatments for Lower Urinary Tract Symptomsin People with Benign Prostatic Hyperplasia: AReview of Clinical Effectiveness. Ottawa (ON):Canadian Agency for Drugs and Technologies inHealth; 2019.

  22. Silva V, Grande AJ, Peccin MS. Physical activityfor lower urinary tract symptoms secondaryto benign prostatic obstruction. The CochraneDatabase of Systematic Reviews. 2019;4(4):CD012044. https://doi.org/10.1002/14651858.CD012044.pub2.

  23. Silva-Araujo HD, Barreto-Gutiérrez M, Flores-Fernández OC, Rodríguez-Fernández MV.Rol de la laparoscopía en el tratamiento de lahiperplasia prostática benigna: experienciaLATAM. Revista Mexicana de Urología.2022;82(3): 1–8. https://doi.org/10.48193/revistamexicanadeurologa.v82i3.876.

  24. Chamorro Jimenez L, Lanazca DelaCruz C,Figueroa Gamarra L. Percepción del tamizajede cáncer de próstata en Huánuco, Perú.2018. Revista Peruana de investigación en salud.2019;3(4): 158–166.

  25. Molina-Barrera ÁM, Ramos-Ulloa JG, Becerra-Méndez LM, García-Valencia J, Varela-RamírezR, Silva-Chacón D. Predictors of biochemicalrecurrence after radical prostatectomy at anoncology reference center in Colombia. ArchivosEspanoles De Urologia. 2021;74(7): 656–663.

  26. Chandrasekar T, Herrera-Caceres JO, KlotzL. Active surveillance in intermediate riskprostate cancer. Archivos Espanoles De Urologia.2019;72(2): 157–166.

  27. Irwin DE, Milsom I, Kopp Z, Abrams P,Artibani W, Herschorn S. Prevalence, severity,and symptom bother of lower urinary tractsymptoms among men in the EPIC study:impact of overactive bladder. European Urology.2009;56(1): 14–20. https://doi.org/10.1016/j.eururo.2009.02.026.

  28. Secretaria de Salud. NORMA Oficial MexicanaNOM-048-SSA2-2017, Para la prevención,detección, diagnóstico, tratamiento, vigilanciaepidemiológica y promoción de la salud sobre elcrecimiento prostático benigno (hiperplasia de lapróstata) y cáncer de próstata (tumor maligno dela próstata). 2017.

  29. Fu X, Wang Y, Lu Y, Liu J, Li H. Associationbetween metabolic syndrome and benignprostatic hyperplasia: The underlying molecularconnection. Life Sciences. 2024;358: 123192.https://doi.org/10.1016/j.lfs.2024.123192.

  30. Leslie SW, Sajjad H, Singh S. Nocturia. In:StatPearls. Treasure Island (FL): StatPearlsPublishing; 2024.




2020     |     www.medigraphic.com